Showing 2 posts of 2 posts found.

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023
Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …

Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal

June 20, 2023
Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera

Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …

Latest content